Effects of combination treatment with transcranial magnetic stimulation and bone marrow mesenchymal stem cell transplantation or Raf inhibition on spinal cord injury in rats

Feng,Sining; Wang,Shuai; Sun,Shi; Su,Hao; Zhang,Lixin

doi:10.3892/mmr.2021.11934

Effects of combination treatment with transcranial magnetic stimulation and bone marrow mesenchymal stem cell transplantation or Raf inhibition on spinal cord injury in rats

Authors:
- Sining Feng
- Shuai Wang
- Shi Sun
- Hao Su
- Lixin Zhang
View Affiliations

Affiliations: Department of Rehabilitation, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China
Published online on: February 23, 2021 https://doi.org/10.3892/mmr.2021.11934
Article Number: 294
Copyright: © Feng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Spinal cord injury (SCI) remains a global challenge due to limited treatment strategies. Transcranial magnetic stimulation (TMS), bone marrow mesenchymal stem cell (BMSC) transplantation and downregulation of Raf/MEK/ERK signaling effectively improve SCI. The combination of BMSCs and TMS displays synergistic effects on vascular dementia. However, whether TMS displays a synergistic effect when combined with BMSC transplantation or Raf inhibitor (RafI) therapy for the treatment of SCI is not completely understood. The present study aimed to compare the therapeutic effect of monotherapy and combination therapy on SCI. In the present study, 8‑week‑old female Sprague Dawley rats were used to establish a model of SCI using the weight‑drop method followed by treatment with monotherapy (TMS, BMSCs or RafI) or combination therapy (TMS+BMSCs or TMS+RafI). The effect of monotherapy and combination therapy on locomotor function, pathological alterations, neuronal apoptosis and expression of axonal regeneration‑associated factors and Raf/MEK/ERK signaling‑associated proteins in the spinal cord was analyzed by Basso, Beattie and Bresnahan (BBB) scoring, hematoxylin and eosin staining, TUNEL‑neuronal nuclei (NeuN) staining and immunofluorescence or western blotting, respectively. The results demonstrated that compared with untreated SCI model rats, monotherapy significantly enhanced locomotor functional recovery, as evidenced by higher BBB scores, and slightly alleviated histopathological lesions of the spinal cord in SCI model rats. Furthermore, monotherapy markedly suppressed neuronal apoptosis and promoted axonal regeneration, as well as inhibiting astroglial activation in SCI model rats. The aforementioned results were demonstrated by significantly decreased numbers of apoptotic neurons, markedly decreased expression levels of glial fibrillary acidic protein (GFAP), significantly increased numbers of NeuN+ cells, markedly increased expression levels of growth‑associated protein 43 (GAP‑43) and significantly upregulated nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF) expression levels in monotherapy groups (excluding the RafI monotherapy group) compared with untreated SCI model rats. In addition, monotherapy markedly suppressed activation of the Raf/MEK/ERK signaling pathway, as evidenced by significantly reduced p‑Raf/Raf, p‑MEK/MEK and p‑ERK/ERK protein expression levels in monotherapy groups (excluding the BMSC monotherapy group) compared with untreated SCI model rats. Notably, combination therapy further alleviated SCI‑induced spinal cord lesions and neuronal apoptosis, increased GAP‑43, NGF and BDNF expression levels, downregulated GFAP expression levels and inhibited activation of the Raf/MEK/ERK signaling pathway in SCI model rats compared with the corresponding monotherapy groups. Therefore, it was hypothesized that compared with monotherapy, combination therapy displayed an improved therapeutic effect on SCI by further suppressing Raf/MEK/ERK signaling. The results of the present study provided an important basis for the clinical application of combination therapy.

View Figures

View References

1	Kim YH, Ha KY and Kim SI: Spinal cord injury and related clinical trials. Clin Orthop Surg. 9:1–9. 2017. View Article : Google Scholar : PubMed/NCBI
2	Wang YT, Lu XM, Chen KT, Shu YH and Qiu CH: Immunotherapy strategies for spinal cord injury. Curr Pharm Biotechnol. 16:492–505. 2015. View Article : Google Scholar : PubMed/NCBI
3	Manchikanti L, Singh V, Datta S, Cohen SP and Hirsch JA; American Society of Interventional Pain Physicians, : Comprehensive review of epidemiology, scope, and impact of spinal pain. Pain Physician. 12:E35–E70. 2009.PubMed/NCBI
4	Kwon BK, Tetzlaff W, Grauer JN, Beiner J and Vaccaro AR: Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine J. 4:451–464. 2004. View Article : Google Scholar : PubMed/NCBI
5	Spinal Cord Injury (SCI) 2016 facts and figures at a glance. J Spinal Cord Med. 39:493–494. 2016. View Article : Google Scholar : PubMed/NCBI
6	Ditunno JF Jr: Functional outcomes in spinal cord injury (SCI): Quality care versus cost containment. J Spinal Cord Med. 20:1–7. 1997. View Article : Google Scholar : PubMed/NCBI
7	McDonald JW and Sadowsky C: Spinal-cord injury. Lancet. 359:417–425. 2002. View Article : Google Scholar : PubMed/NCBI
8	Rowland JW, Hawryluk GW, Kwon B and Fehlings MG: Current status of acute spinal cord injury pathophysiology and emerging therapies: Promise on the horizon. Neurosurg Focus. 25:E22008. View Article : Google Scholar : PubMed/NCBI
9	Ren Z, Chen X, Yang J, Kress BT, Tong J, Liu H, Takano T, Zhao Y and Nedergaard M: Improved axonal regeneration after spinal cord injury in mice with conditional deletion of ephrin B2 under the GFAP promoter. Neuroscience. 241:89–99. 2013. View Article : Google Scholar : PubMed/NCBI
10	Yang T, Dai Y, Chen G and Cui S: Dissecting the dual role of the glial scar and scar-forming astrocytes in spinal cord injury. Front Cell Neurosci. 14:782020. View Article : Google Scholar : PubMed/NCBI
11	Benninger F, Glat MJ, Offen D and Steiner I: Glial fibrillary acidic protein as a marker of astrocytic activation in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Clin Neurosci. 26:75–78. 2016. View Article : Google Scholar : PubMed/NCBI
12	Okada S, Hara M, Kobayakawa K, Matsumoto Y and Nakashima Y: Astrocyte reactivity and astrogliosis after spinal cord injury. Neurosci Res. 126:39–43. 2018. View Article : Google Scholar : PubMed/NCBI
13	Curtis R, Green D, Lindsay RM and Wilkin GP: Up-regulation of GAP-43 and growth of axons in rat spinal cord after compression injury. J Neurocytol. 22:51–64. 1993. View Article : Google Scholar : PubMed/NCBI
14	Keefe KM, Sheikh IS and Smith GM: Targeting neurotrophins to specific populations of neurons: NGF, BDNF, and NT-3 and their relevance for treatment of spinal cord injury. Int J Mol Sci. 18:5482017. View Article : Google Scholar
15	Barker AT, Jalinous R and Freeston IL: Non-invasive magnetic stimulation of human motor cortex. Lancet. 1:1106–1107. 1985. View Article : Google Scholar : PubMed/NCBI
16	Pashut T, Wolfus S, Friedman A, Lavidor M, Bar-Gad I, Yeshurun Y and Korngreen A: Mechanisms of magnetic stimulation of central nervous system neurons. PLoS Comput Biol. 7:e10020222011. View Article : Google Scholar : PubMed/NCBI
17	Rothwell JC: Techniques and mechanisms of action of transcranial stimulation of the human motor cortex. J Neurosci Methods. 74:113–122. 1997. View Article : Google Scholar : PubMed/NCBI
18	Cantello R: Applications of transcranial magnetic stimulation in movement disorders. J Clin Neurophysiol. 19:272–293. 2002. View Article : Google Scholar : PubMed/NCBI
19	de Araujo AVL, Barbosa VRN, Galdino GS, Fregni F, Massetti T, Fontes SL, de Oliveira Silva D, da Silva TD, Monteiro CBM, Tonks J and Magalhães FH: Effects of high-frequency transcranial magnetic stimulation on functional performance in individuals with incomplete spinal cord injury: Study protocol for a randomized controlled trial. Trials. 18:5222017. View Article : Google Scholar : PubMed/NCBI
20	Kumru H, Kofler M, Valls-Sole J and Vidal J: Brainstem reflex excitability after high-frequency repetitive transcranial magnetic stimulation in healthy and spinal cord injury subjects. Brain Res Bull. 147:86–91. 2019. View Article : Google Scholar : PubMed/NCBI
21	Aznar J and Sanchez JL: Embryonic stem cells: Are useful in clinic treatments? J Physiol Biochem. 67:141–144. 2011. View Article : Google Scholar : PubMed/NCBI
22	Ogawa Y, Sawamoto K, Miyata T, Miyao S, Watanabe M, Nakamura M, Bregman BS, Koike M, Uchiyama Y, Toyama Y and Okano H: Transplantation of in vitro-expanded fetal neural progenitor cells results in neurogenesis and functional recovery after spinal cord contusion injury in adult rats. J Neurosci Res. 69:925–933. 2002. View Article : Google Scholar : PubMed/NCBI
23	Tsuji O, Miura K, Okada Y, Fujiyoshi K, Mukaino M, Nagoshi N, Kitamura K, Kumagai G, Nishino M, Tomisato S, et al: Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injury. Proc Natl Acad Sci USA. 107:12704–12709. 2010. View Article : Google Scholar : PubMed/NCBI
24	Miao C, Lei M, Hu W, Han S and Wang Q: A brief review: The therapeutic potential of bone marrow mesenchymal stem cells in myocardial infarction. Stem Cell Res Ther. 8:2422017. View Article : Google Scholar : PubMed/NCBI
25	Fehlings MG and Vawda R: Cellular treatments for spinal cord injury: The time is right for clinical trials. Neurotherapeutics. 8:704–720. 2011. View Article : Google Scholar : PubMed/NCBI
26	Mannoji C, Koda M, Kamiya K, Dezawa M, Hashimoto M, Furuya T, Okawa A, Takahashi K and Yamazaki M: Transplantation of human bone marrow stromal cell-derived neuroregenrative cells promotes functional recovery after spinal cord injury in mice. Acta Neurobiol Exp (Wars). 74:479–488. 2014.PubMed/NCBI
27	Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
28	Cao FJ, Zhang X, Liu T, Li XW, Malik M and Feng SQ: Up-regulation of Ras/Raf/ERK1/2 signaling in the spinal cord impairs neural cell migration, neurogenesis, synapse formation, and dendritic spine development. Chin Med J (Engl). 126:3879–3885. 2013.PubMed/NCBI
29	Liu T, Cao FJ, Xu DD, Xu YQ and Feng SQ: Upregulated Ras/Raf/ERK1/2 signaling pathway: A new hope in the repair of spinal cord injury. Neural Regen Res. 10:792–796. 2015. View Article : Google Scholar : PubMed/NCBI
30	Sugaya T, Kanno H, Matsuda M, Handa K, Tateda S, Murakami T, Ozawa H and Itoi E: B-RAF(V600E) inhibitor dabrafenib attenuates RIPK3-mediated necroptosis and promotes functional recovery after spinal cord injury. Cells. 8:15822019. View Article : Google Scholar
31	Woller SA, Malik JS, Aceves M and Hook MA: Morphine self-administration following spinal cord injury. J Neurotrauma. 31:1570–1583. 2014. View Article : Google Scholar : PubMed/NCBI
32	Basso DM, Beattie MS and Bresnahan JC: Graded histological and locomotor outcomes after spinal cord contusion using the NYU weight-drop device versus transection. Exp Neurol. 139:244–256. 1996. View Article : Google Scholar : PubMed/NCBI
33	Sandhir R, Gregory E, He YY and Berman NE: Upregulation of inflammatory mediators in a model of chronic pain after spinal cord injury. Neurochem Res. 36:856–862. 2011. View Article : Google Scholar : PubMed/NCBI
34	National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals, . Guide for the Care and Use of Laboratory Animals, 8th edition. National Academies Press (US); Washington, DC: 2011
35	Chen Q, Duan X, Xu M, Fan H, Dong Y, Wu H, Zhang M, Liu Y, Nan Z, Deng S and Liu X: BMSC-EVs regulate Th17 cell differentiation in UC via H3K27me3. Mol Immunol. 118:191–200. 2020. View Article : Google Scholar : PubMed/NCBI
36	Eckert MJ and Martin MJ: Trauma: Spinal cord injury. Surg Clin North Am. 97:1031–1045. 2017. View Article : Google Scholar : PubMed/NCBI
37	Lee BB, Cripps RA, Fitzharris M and Wing PC: The global map for traumatic spinal cord injury epidemiology: Update 2011, global incidence rate. Spinal Cord. 52:110–116. 2014. View Article : Google Scholar : PubMed/NCBI
38	Awad BI, Carmody MA, Zhang X, Lin VW and Steinmetz MP: Transcranial magnetic stimulation after spinal cord injury. World Neurosurg. 83:232–235. 2015. View Article : Google Scholar : PubMed/NCBI
39	Cha HG, Ji SG and Kim MK: Effect of high-frequency repetitive transcranial magnetic stimulation on motor cortical excitability and sensory nerve conduction velocity in subacute-stage incomplete spinal cord injury patients. J Phys Ther Sci. 28:2002–2004. 2016. View Article : Google Scholar : PubMed/NCBI
40	Lin L, Lin H, Bai S, Zheng L and Zhang X: Bone marrow mesenchymal stem cells (BMSCs) improved functional recovery of spinal cord injury partly by promoting axonal regeneration. Neurochem Int. 115:80–84. 2018. View Article : Google Scholar : PubMed/NCBI
41	Wu S, Suzuki Y, Ejiri Y, Noda T, Bai H, Kitada M, Kataoka K, Ohta M, Chou H and Ide C: Bone marrow stromal cells enhance differentiation of cocultured neurosphere cells and promote regeneration of injured spinal cord. J Neurosci Res. 72:343–351. 2003. View Article : Google Scholar : PubMed/NCBI
42	Wang F, Zhang C, Hou S and Geng X: Synergistic effects of mesenchymal stem cell transplantation and repetitive transcranial magnetic stimulation on promoting autophagy and synaptic plasticity in vascular dementia. J Gerontol A Biol Sci Med Sci. 74:1341–1350. 2019. View Article : Google Scholar : PubMed/NCBI
43	Anderson KD, Abdul M and Steward O: Quantitative assessment of deficits and recovery of forelimb motor function after cervical spinal cord injury in mice. Exp Neurol. 190:184–191. 2004. View Article : Google Scholar : PubMed/NCBI
44	Basso DM, Beattie MS and Bresnahan JC: A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma. 12:1–21. 1995. View Article : Google Scholar : PubMed/NCBI
45	Poirrier AL, Nyssen Y, Scholtes F, Multon S, Rinkin C, Weber G, Bouhy D, Brook G, Franzen R and Schoenen J: Repetitive transcranial magnetic stimulation improves open field locomotor recovery after low but not high thoracic spinal cord compression-injury in adult rats. J Neurosci Res. 75:253–261. 2004. View Article : Google Scholar : PubMed/NCBI
46	Ning GZ, Song WY, Xu H, Zhu RS, Wu QL, Wu Y, Zhu SB, Li JQ, Wang M, Qu ZG and Feng SQ: Bone marrow mesenchymal stem cells stimulated with low-intensity pulsed ultrasound: Better choice of transplantation treatment for spinal cord injury: Treatment for SCI by LIPUS-BMSCs transplantation. CNS Neurosci Ther. 25:496–508. 2019. View Article : Google Scholar : PubMed/NCBI
47	Elmore S: Apoptosis: A review of programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
48	Mazarakis ND, Edwards AD and Mehmet H: Apoptosis in neural development and disease. Arch Dis Child Fetal Neonatal Ed. 77:F165–F170. 1997. View Article : Google Scholar : PubMed/NCBI
49	Kim DH, Vaccaro AR, Henderson FC and Benzel EC: Molecular biology of cervical myelopathy and spinal cord injury: Role of oligodendrocyte apoptosis. Spine J. 3:510–519. 2003. View Article : Google Scholar : PubMed/NCBI
50	Lan WB, Lin JH, Chen XW, Wu CY, Zhong GX, Zhang LQ, Lin WP, Liu WN, Li X and Lin JL: Overexpressing neuroglobin improves functional recovery by inhibiting neuronal apoptosis after spinal cord injury. Brain Res. 1562:100–108. 2014. View Article : Google Scholar : PubMed/NCBI
51	Zhang H, Wu F, Kong X, Yang J, Chen H, Deng L, Cheng Y, Ye L, Zhu S, Zhang X, et al: Nerve growth factor improves functional recovery by inhibiting endoplasmic reticulum stress-induced neuronal apoptosis in rats with spinal cord injury. J Transl Med. 12:1302014. View Article : Google Scholar : PubMed/NCBI
52	Rong W, Wang J, Liu X, Jiang L, Wei F, Hu X, Han X and Liu Z: Naringin treatment improves functional recovery by increasing BDNF and VEGF expression, inhibiting neuronal apoptosis after spinal cord injury. Neurochem Res. 37:1615–1623. 2012. View Article : Google Scholar : PubMed/NCBI
53	Madsen JR, MacDonald P, Irwin N, Goldberg DE, Yao GL, Meiri KF, Rimm IJ, Stieg PE and Benowitz LI: Tacrolimus (FK506) increases neuronal expression of GAP-43 and improves functional recovery after spinal cord injury in rats. Exp Neurol. 154:673–683. 1998. View Article : Google Scholar : PubMed/NCBI
54	Brenner M, Kisseberth WC, Su Y, Besnard F and Messing A: GFAP promoter directs astrocyte-specific expression in transgenic mice. J Neurosci. 14:1030–1037. 1994. View Article : Google Scholar : PubMed/NCBI
55	Blais M, Levesque P, Bellenfant S and Berthod F: Nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3 and glial-derived neurotrophic factor enhance angiogenesis in a tissue-engineered in vitro model. Tissue Eng Part A. 19:1655–1664. 2013. View Article : Google Scholar : PubMed/NCBI
56	Feng D, Wang B, Ma Y, Shi W, Tao K, Zeng W, Cai Q, Zhang Z and Qin H: The Ras/Raf/erk pathway mediates the subarachnoid hemorrhage-induced apoptosis of hippocampal neurons through phosphorylation of p53. Mol Neurobiol. 53:5737–5748. 2016. View Article : Google Scholar : PubMed/NCBI